Cerebral venous thrombosis requiring invasive treatment for elevated intracranial pressure in women with combined hormonal contraceptive intake: risk factors, anatomical distribution, and clinical presentation

*Michel Roethlisberger, MD,1 Lara Gut, MD,1 Daniel Walter Zumofen, MD,1,2 Urs Fisch, MD, PhD,3 Oliver Boss, MD,1 Nicolai Maldaner, MD,4 Davide Marco Croci, MD,1 Ethan Taub, MD,1 Natascia Corti, MD,4 Jan-Karl Burkhardt, MD,5,6 Raphael Guzman, MD,1 Oliver Bozinov, MD,4 and Luigi Mariani, MD1

Departments of 1Neurosurgery and 3Neurology, and 2Division of Diagnostic and Interventional Neuroradiology, Department of Radiology, University Hospital Basel and University of Basel, Basel; Departments of 4Clinical Pharmacology and 6Neurosurgery, University Hospital Zürich and University of Zürich, Zürich, Switzerland; and 5Department of Neurological Surgery, NYU School of Medicine, NYU Langone Medical Center, New York, New York

OBJECTIVE  Women taking combined hormonal contraceptives (CHCs) are generally considered to be at low risk for cerebral venous thrombosis (CVT). When it does occur, however, intensive care and neurosurgical management may, in rare cases, be needed for the control of elevated intracranial pressure (ICP). The use of nonsurgical strategies such as barbiturate coma and induced hypothermia has never been reported in this context. The objective of this study is to determine predictive factors for invasive or surgical ICP treatment and the potential complications of nonsurgical strategies in this population.

METHODS  The authors conducted a 2-center, retrospective chart review of 168 cases of CVT in women between 2000 and 2012. Eligible patients were classified as having had a mild or a severe clinical course, the latter category including all patients who underwent invasive or surgical ICP treatment and all who had an unfavorable outcome (modified Rankin Scale score ≥ 3 or Glasgow Outcome Scale score ≤ 3). The Mann-Whitney U-test was used for continuous parameters and Fisher’s exact test for categorical parameters, and odds ratios were calculated with statistical significance set at p ≤ 0.05.

RESULTS  Of the 168 patients, 57 (age range 16–49 years) were determined to be eligible for the study. Six patients (10.5%) required invasive or surgical ICP treatment. Three patients (5.3%) developed refractory ICP > 30 mm Hg despite early surgical decompression; 2 of them (3.5%) were treated with barbiturate coma and induced hypothermia, with documented infectious, thromboembolic, and hemorrhagic complications. Coma on admission, thrombosis of the deep venous system with consecutive hydrocephalus, intraventricular hemorrhage, and hemorrhagic venous infarction were associated with a higher frequency of surgical intervention. Coma, quadripareisis on admission, and hydrocephalus were more commonly seen among women with unfavorable outcomes. Thrombosis of the transverse sinus was less common in patients with an unfavorable outcome, with similar distribution in patients needing invasive or surgical ICP treatment.

CONCLUSIONS  The need for invasive or surgical ICP treatment in women taking CHCs who have CVT is partly predictable on the basis of the clinical and radiological findings on admission. The use of nonsurgical treatments for refractory ICP, such as barbiturate coma and induced hypothermia, is associated with systemic infectious and hematological complications and may worsen morbidity in this patient population. The significance of these factors should be studied in larger multicenter cohorts.

https://thejns.org/doi/abs/10.3171/2018.4.FOCUS1891

KEYWORDS  cerebral venous thrombosis; combined hormonal contraceptive intake; intracranial pressure; decompressive surgery; barbiturate coma; induced hypothermia
Cerebral venous thrombosis (CVT) is a rare event, with an incidence of 5 per million per year, and accounts for 0.5% to 1% of all strokes. CVT is 3 times more common in women than in men and is also more common in patients under 40 years of age. Recent studies have shown that the overall incidence of CVT may be even higher than previously thought because its clinical features may be subtle; population-based studies are pending.

The intake of combined hormonal contraceptives (CHCs) increases the risk of CVT by a factor of 7.6 and is very common. Besides obesity, which has recently been shown to double the risk of CVT in combination with CHC intake, a variety of inherited and acquired risk factors are described in the literature. Cigarette smoking combined with CHC intake and a positive family history or personal history of a prior thrombotic event are known to be important risk factors for deep vein thrombosis and pulmonary thromboembolism but have not been shown to be so for CVT.

CVT can be successfully treated with anticoagulation (e.g., with intravenous or subcutaneous heparin) in most cases. The outcome of CVT can be severe or fatal, however: the acute 30-day mortality is 3.4%, and the rate of dependency on nursing care at the time of discharge is 14.6%. A small percentage of patients sustain clinical complications necessitating intensive care management or neurosurgical interventions. In general, invasive or surgical intracranial pressure (ICP) treatment is rarely needed. Endovascular treatment options using modern approaches are emerging within this context and seem to be safe and effective when conventional management fails. Retrospective and prospective observational studies suggest that early decompressive surgery prevents death and does not result in an excess of severe disability, but specific data on additional medical treatment in CVT remain scarce. In particular, the use of barbiturate coma and induced hypothermia in patients with refractory ICP due to CVT has not been described in the literature.

The primary objective of this retrospective study was to determine risk factors and predictive factors for surgical interventions and unfavorable outcome in a homogeneous group of nonpregnant women who sustained an unprovoked CVT with concurrent or recent CHC intake. The secondary objective was to determine the complications of nonsurgical ICP treatment options (barbiturate coma and induced hypothermia) in the subgroup of patients with refractory ICP.

Methods

Study Centers

This study was performed in 2 large tertiary care university hospitals (Basel and Zurich). The local ethics committees approved the study in December 2014 (Basel) and October 2015 (Zürich). Both local ethics committees waived the need for obtaining written informed consent. This study is a retrospective analysis of preexisting data without intervention and therefore does not require clinical trial registration. One author (L.G.) conducted retrospective patient chart review for both centers.

Inclusion and Exclusion Criteria

Female patients with diagnosed cerebral venous thrombosis (CVT) of the dural sinuses, involvement of the deep venous system (DCVT), cortical venous thrombosis, or with thrombosis of the jugular system based on the International Statistical Classification of Diseases and Related Health Problems, as well as documented intake of CHCs were included. The criteria for exclusion were 1) missing information about the diagnosis or CHC intake and 2) the documented presence of CVT-provoking factors, including pregnancy, infection, and previous surgery (Fig. 1).

Study Variables

Treatment information included conservative management, intensive care, invasive or surgical ICP treatment, and barbiturate coma and/or induced hypothermia. Outcome values at discharge were scores on the modified Rankin Scale (mRS) and Glasgow Outcome Scale (GOS), dichotomized into favorable and unfavorable categories (favorable: mRS score ≤ 2 or GOS score ≥ 4 points; unfavorable: mRS score ≥ 3 or GOS score ≤ 3 points). On the basis of this information, the clinical course was designated as “mild” if it involved conservative treatment on the ward or only short-term sedation for seizures in an intensive care unit, no need for invasive or surgical ICP treatment, and a favorable outcome on discharge. In all other cases, the clinical course was designated as “severe.” Based on computed tomography (CT) and magnetic resonance imaging (MRI) with venographic studies (CT venography [CTV] and MR venography [MRV]), 5 radiological variables were documented for each patient: the type and extent of thrombosis, hemorrhage, edema, venous infarction, and hydrocephalus. Five clinical variables were documented as well: Increased intracranial pressure (ICP) was defined as a pressure greater than 15 mm Hg by lumbar puncture or evident clinical signs of intracranial hypertension (e.g., a combination of headaches, nausea, vomiting, altered consciousness, papilledema). The clinical signs assessed on admission and discharge that were considered were the Glasgow Coma Scale (GCS) score, new focal neurological deficits, cranial nerve deficits, and seizures (Fig. 1).

Statistical Analysis

Continuous variables are reported as the mean or median and range, categorical variables as absolute numbers and percentages. Comparisons between groups were performed with the Mann-Whitney U-test for continuous parameters and Fisher’s exact test for categorical parameters. Odds ratios and corresponding p values were calculated without a multivariate model because of the small sample size. Statistical significance was set at p ≤ 0.05.

Results

The initial screening identified 168 patients in both centers within a time period of 12 years from 2000 to 2012. A total of 111 did not meet the inclusion criteria because of male sex; having hard risk factors, including pregnancy, previous surgery, or infection; or missing information re-
regarding CHC intake. Thus 57 patients were eligible for analysis and were dichotomized.

**Patient Characteristics**

All included patients were women; their ages ranged from 16 to 49 years. Third-generation CHCs containing desogestrel or gestoden were the most commonly used type of CHC in both the mild and the severe clinical course groups. There was no significant difference between the groups with respect to risk factor distribution (Table 1).

**Surgical and Medical Treatment for Elevated ICP (> 30 mm Hg)**

Six of 57 patients (10.5%) underwent surgery. Nine patients (15.8%) underwent intensive care management, 3 of them with short-term sedation because of generalized epileptic seizures (these 3 patients were not in the severe
clinical course group). Three patients displayed refractory ICP elevation leading to additional medical ICP treatment with associated infectious and hematological complications (Table 2).

Outcome at Discharge

The majority of patients (87.7%) were discharged with an mRS score ≤ 2 and a GOS score ≥ 4. The in-hospital mortality rate was 1.8% (n = 1). Patients who underwent surgical ICP treatment were discharged with a favorable clinical outcome in 2 (33.3%) and an unfavorable outcome in 4 cases (66.7%) (Table 2).

Predictive Radiological Characteristics at Admission

Extent of Thrombosis

Compared to women with a mild clinical course, women who underwent invasive or surgical ICP treatment more frequently suffered from DCVT, including thrombosis of the great vein of Galen, bilateral thrombosis of the basal veins of Rosenthal, and bilateral thrombosis of the internal cerebral veins. However, in women with a severe course and unfavorable outcome, there were significantly fewer cases of thrombosis in the transverse sinus, without difference in laterality. Finally, there was no statistically significant between-groups difference in the incidence of DCVT (Tables 3 and 4).

Hemorrhage, Edema, and Ischemia

Women with a severe clinical course and surgical interventions more frequently presented with intraventricular as well parenchymal hemorrhage in the context of venous infarction as well as involvement of deep anatomical structures (Table 3).

Hydrocephalus

Women with CVT and hydrocephalus more frequently had DCVT (83.3% vs 17.6%), involvement of deep anatomical structures (83.3% vs 17.6%), and thrombosis of the straight sinus (83.3% vs 29.4%), while thrombosis of the superior sagittal sinus was less likely to be present. Hydrocephalus was more common in surgically treated patients and those with an unfavorable outcome (Tables 3 and 4, Figs. 2 and 3).

Clinical Presentation on Admission

Glasgow Coma Scale Scores

Overall, 45 patients (78.9%) presented with a GCS score of 13–15, 2 (3.5%) with a GCS score of 9–12, and 3 (5.3%) with a GCS score of 3–8 on admission. The median GCS score on admission was significantly lower in women who underwent invasive or surgical ICP treatment and women with an unfavorable outcome (Table 5, Fig. 2).

Clinical Signs of Increased ICP

Clinical signs of increased ICP were more common among women with a severe clinical course (Table 5). A similar distribution was found among women who underwent invasive or surgical ICP treatment (Table 6, Fig. 2).

Focal Neurological Deficits on Admission

Neurological deficits were more frequent in women with a severe clinical course; in particular, quadriplegia on admission was more frequent in women with an unfavorable outcome. One patient (2.1%) in the mild course group had quadriplegia because of bifrontal lesions. In women with an unfavorable outcome, cranial nerve deficits and impairment of eye movement at admission were more frequently documented (Table 7, Fig. 3).

Discussion

The use of combined hormonal contraceptives (CHCs) is a well-known risk factor for unprovoked CVT.1 The current study supports this, reporting a frequency of CHC usage in this group of patients who sustained CVT that is approximately twice as high as the application of hormonal contraceptives in the general Swiss population.6 Among the various types of CHCs, third-generation CHCs containing desogestrel or gestoden reportedly confer the highest risk for CVT.1 In accordance with the findings of a prior study, cigarette smoking was approximately as common in our patient group as in the general Swiss population (Table 1).3,10,29

Aside from the clinical features, the current diagnosis of CVT is mainly based on imaging studies.28 The anatomical distribution of CVT within this study was similar to that reported in previous studies.13 Parenchymal lesions such as hemorrhage, venous infarction, ischemia, or edema may facilitate the radiological diagnosis of CVT but are only present in 60%–70% of patients.13 Radiological signs
TABLE 2. Patient characteristics, complications, and outcomes in cases requiring invasive and/or surgical treatment for hydrocephalus or elevated ICP

| Case No. | Age (yrs)* | Risk Factors | GCS on Admission | Parenchymal Lesion | Hydrocephalus | Surgical Tx | Refractory ICP (>30 mm Hg) | Medical ICP Tx | Catheter-Induced Hypothermia | Complications of Invasive &/or Surgical Tx in Comb w/ Mandatory Anticoag | Outcome (mRS/GOS) |
|----------|------------|--------------|------------------|-------------------|--------------|------------|---------------------|----------------|-----------------------------|---------------------------------|-----------------|
| 1        | 37         | CHC (undefined), obesity | 13 | VI: left temp-par-occ | Yes | Hematoma evac, decompr craniectomy, ICP probe, EVD | Yes | Osmotherapy, barbit coma, hypervent, THAM | IV: 91.4°F (33°C) for 11 days | Large hematoma in adductor compartment (catheter site) needing surgical evac; necrotizing fasciitis w/ septic shock needing surgical debridement | 2/4 |
| 2        | 33         | CHC (undefined), nicotine abuse | 5 | VI: left temp, extensive hemorrhage | No | Decomp craniectomy, hematoma evac | Yes | Intubation, midazolam/sufentanil | No | Death w/in 12 hrs | 6/1 |
| 3        | 19         | 4th-gen CHC, APS (type II) | 9 | SAH: right; VI: right par-temp & right thalamus | Yes | EVD, VP shunt | Yes | Osmotherapy, midazolam/sufentanil, barbit coma | No | EVDAI, SIRS, DIC | 3/3 |
| 4        | 43         | 4th-gen CHC, obesity | 7 | VI: left basal ganglia & diencephalon; IVH: left | Yes | ICP probe, multiple EVDs, decompr craniectomy | Yes | Osmotherapy, midazolam/sufentanil, barbit coma | IV: 91.4°F (33°C) for 6 days, 95°F (35°C) for 14 days | EVDAI, SIRS, hepatopathy, surgical site hemorrhage (parenchymal & subgaleal), femoral DVT (catheter site) | 5/3 |
| 5        | 30         | 3rd-gen CHC, dehydration | 8 | VI: left basal ganglia & thalamus | Yes | EVD | No | No | No | None | 3/3 |
| 6        | 34         | 4th-gen CHC, heterozygous prothrombin mutation | 15 | VI: bilat thalamus, midbrain, left int capsule; IVH: bilat | Yes | EVD | No | No | No | None | 1/5 |

Anticoag = anticoagulation; APS = antiphospholipid antibody syndrome; barb = barbiturate; comb = combination; decompr = decompressive; DIC = disseminated intravascular coagulation; evac = evacuation; EVD = external ventricular drain; EVDAI = EVD-associated infection; hypervent = hyperventilation; ICP = intracranial pressure; int = internal; IV = intravenous; IVH = intraventricular hemorrhage; occ = occipital; par = parietal; SAH = subarachnoid hemorrhage, SIRS = systemic inflammatory response syndrome; temp = temporal; THAM = trishydroxymethylaminomethane; Tx = treatment; VI = venous infarction (hemorrhagic or non-hemorrhagic); VP = ventriculoperitoneal.

This table presents the characteristics of 6 out 57 (10.5%) women with CVT and CHC intake with medically and surgically treated hydrocephalus or elevated ICP, as well as their medical, invasive, and/or surgical treatment and resulting complications.

* All patients were female.
of hydrocephalus range from 4%–20%, 32,35 and appear to be associated with affected anatomical structures related to the foramina of Monro and the cerebral aqueduct.

The main cause of elevated ICP in acute CVT is trans-tentorial herniation due to unilateral focal mass effect or to diffuse parenchymal lesions with cerebral edema. 8 According to the current guidelines of the European Academy of Neurology, published in 2017, there is still no more than scant evidence for the treatment of elevated ICP in

### TABLE 3. Differences in anatomical distribution of CVT in women in need of invasive ICP management, EVD, or decompressive procedures compared to conservatively treated controls

| Anatomical Extent of CVT at Admission | No ICP Tx (n = 51 [89.5%]) | Invasive or Surgical ICP Tx (n = 6 [10.5%]) | p Value |
|--------------------------------------|----------------------------|------------------------------------------|---------|
| Affecte

| Median no. of affected venous locations per pt | 3 | 5 | 0.165† |
|-----------------------------------------------|---|---|-------|
| Sinus veins | 49 (96.1) | 6 (100) | — |
| Transverse sinus | 46 (90.2) | 4 (66.7) | 0.153‡ |
| Left | 20 (43.5) | 2 (50.0) | — |
| Right | 26 (65.5) | 2 (50.0) | — |
| Sigmoid sinus | 39 (76.5) | 4 (66.7) | 0.629‡ |
| Superior sagittal | 25 (43.9) | 1 (16.7) | 0.205‡ |
| Inferior sagittal | 2 (3.9) | 0 (0.0) | — |
| Straight sinus | 16 (31.4) | 4 (66.7) | 0.170‡ |
| Torcular herophili§ | 5 (9.8) | 2 (33.3) | 0.153‡ |
| Deep cerebral veins | 10 (19.6) | 4 (66.7) | 0.027‡ |
| Great vein of Galen | 8 (15.7) | 4 (66.7) | 0.015‡ |
| Basal vein of Rosenthal (bilat) | 1 (2.0) | 2 (33.3) | 0.027‡ |
| Internal jugular vein (bilat) | 5 (9.8) | 4 (66.7) | 0.004‡ |
| Internal jugular vein | 23 (45.1) | 2 (33.3) | 0.686‡ |
| Cortical veins | 7 (13.7) | 0 (0.0) | — |

### TABLE 4. Differences in anatomical distribution of CVT in women with favorable outcomes compared to women with unfavorable outcome

| Anatomical Extent of CVT at Admission | Favorable Outcome (n = 50 [87.7%]) | Unfavorable Outcome (n = 7 [12.3%]) | p Value |
|--------------------------------------|-----------------------------------|-----------------------------------|---------|
| Median no. of affected venous locations per pt | 3 | 4 | 0.826† |
| Sinus veins | 48 (96.0) | 7 (100) | — |
| Transverse sinus | 47 (94.0) | 4 (57.1) | 0.034‡ |
| Left | 20 (42.6) | 0 (0.0) | — |
| Right | 27 (57.4) | 3 (42.9) | — |
| Sigmoid sinus | 39 (76.0) | 4 (57.1) | 0.346‡ |
| Superior sagittal | 22 (44.0) | 4 (57.1) | 0.691‡ |
| Inferior sagittal | 2 (4.0) | 0 (0.0) | — |
| Straight sinus | 16 (32.0) | 4 (57.1) | 0.226‡ |
| Torcular herophili§ | 5 (10.0) | 2 (28.6) | 0.202‡ |
| Deep cerebral veins | 11 (22.0) | 3 (42.9) | 0.346‡ |
| Great vein of Galen | 9 (18.0) | 3 (42.9) | 0.154‡ |
| Basal vein of Rosenthal (bilat) | 2 (4.0) | 1 (28.6) | 0.330‡ |
| Internal jugular vein (bilat) | 5 (10.0) | 3 (42.9) | 0.050‡ |
| Internal jugular vein | 24 (48.0) | 1 (14.3) | 0.122‡ |
| Cortical veins | 7 (14.0) | 0 (0.0) | 0.579‡ |

### Radiological variables

| Missing radiological data | 1 (2.0) | 0 (0) | — |
| Parenchymal lesions (n = 56) | 34 (66.6) | 6 (100) | 0.168‡ |
| Hemorrhage | 15 (29.4) | 4 (66.7) | 0.165‡ |
| ICH | 11 (21.6) | 1 (16.7) | — |
| SAH | 4 (7.8) | 1 (16.7) | 0.445‡ |
| IVH | 0 (0.0) | 2 (33.3) | 0.010‡ |
| Edema | 13 (25.5) | 2 (33.3) | 0.654‡ |
| Perifocal | 10 (19.6) | 2 (33.3) | 0.599‡ |
| Generalized | 3 (5.9) | 0 (0.0) | — |
| Ischemia | 6 (11.8) | 1 (16.7) | 0.569‡ |
| Venous infarction | 11 (21.6) | 4 (66.7) | 0.030‡ |
| Nonhemorrhagic | 6 (11.8) | 1 (16.7) | 0.569‡ |
| Hemorrhagic | 5 (9.8) | 3 (50) | 0.032‡ |
| Involvement of basal ganglia &/or thalamus (n = 42) | 8 (15.7) | 4 (66.7) | 0.046‡ |

### Hydrocephalus

| Hydrocephalus (n = 57) | 1 (2.0) | 5 (83.3) | <0.0001‡ |

Pt = patient.
Values represent number of cases (%) unless otherwise indicated. Some patients presented with more than 1 affected location or radiological lesion. Statistical significance was set at p ≤ 0.05.
† Mann-Whitney U-test.
‡ Fisher’s exact chi-square test.
§ Confluence of sinuses.
this rare disease. No randomized controlled trials were found, but a small number of case series and nonrandomized controlled studies seem to show that decompressive surgery prevents death without causing excess severe disability. The available evidence led to a recommendation for surgical decompression in patients with severe CVT early in the time course of the disease.

Endovascular treatment options are increasingly advocated, particularly mechanical thrombectomy, with good recanalization rates. While partial or complete restoration of flow was reached in many cases with multimodal treatment, the mortality rate remained high. Cerebral edema and motor weakness were negative predictors for full recovery, while hormonal etiology correlated with favorable patient outcome. This is in accordance with the finding of our study that unfavorable outcomes are independent of treatment. The endovascular treatment complication rate is described in the literature as approximately 10%, with a full recovery rate of 60%. Therefore, endovascular intervention in this setting constitutes a valuable treatment option in selected cases. However, the optimal method to regain recanalization is yet to be determined.

In some cases, progressive cerebral edema and expansion of hemorrhagic infarcts lead to refractory ICP after surgical decompression. In our case series, ICP monitoring and management were carried out in accordance with current guidelines to attain ICP levels below 20 mm Hg. However, in 3 refractory cases, the patients’ ICP remained elevated above 30 mm Hg even after decompressive surgery. Various nonsurgical treatment options have been assigned level IIb or level III recommendations in the traumatic brain injury management guidelines published by the Brain Trauma Foundation, including ventilation therapies, barbiturate coma, CSF drainage, and prophylactic hypothermia. This last option has been used to prevent and control neurological injuries in different pathologies, including traumatic brain injury and cardiac arrest. Case series describe the use of hypothermia, in combination with barbiturate coma, in patients who have suffered severe SAH and have intractable ICP elevation and/or refractory vasospasm. The benefit of those modalities within the severe course of CVT remains unclear, especially because therapeutic anticoagulation is mandatory. The present study revealed serious infectious and hematologi-

FIG. 2. Clinical and radiological factors associated with surgery for elevated ICP in CVT in women. Surgically treated patients (5 of 6 [83.3%]) were more likely to have hydrocephalus (OR 250.0, 95% CI 13.5–4636.9, p < 0.0001) than patients in the conservatively treated group (1 of 51 [2.0%]). Likewise, these patients (3 of 6 [50%]) were more likely to present with coma (GCS score < 9) on admission (OR 99.0, 95% CI 4.2–2322.6, p = 0.004) than conservatively treated patients (0 of 51 [0.0%]). The surgically treated group more commonly (OR 56.1, 95% CI 2.3–1357.0, p = 0.010) had intraventricular blood on a CT scan (2 of 6 [33.3%]) than the conservatively treated patients (0 of 51 [0.0%]). Clinical signs of raised ICP were more common (OR 30.6, 95% CI 1.6–577.5, p = 0.001) in the surgically treated group (6 of 6 [100%]) than in the conservatively treated group (14 of 51 [27.5%]). Three of 6 (50%) patients in the surgically treated group and 5 of 51 (9.8%) in the conservative group had radiologically confirmed venous hemorrhagic infarction (OR 9.0, 95% CI 1.42–50.1, p = 0.032). Surgically treated patients more commonly (OR 8.2, 95% CI 1.3–51.3, p = 0.027) had thrombosis of the deep venous system (4/6 [66.7%] vs 10/51 [19.6%]). Statistically significant findings are marked as follows: ns = not statistically significant (p > 0.05), *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001, ****p ≤ 0.0001.
cal complications (Table 2). These known side-effects of therapeutic hypothermia are attributable to impaired immune function, poor glycemic control, decreased gastrointestinal motility, and prolonged bleeding time as a result of reduction in the number and function of platelets. In combination with barbiturate coma, those side-effects might even be potentiated.21,22

Coma (GCS < 9) or a major neurological deficit (e.g., quadriparesis) on admission was found to predict an unfavorable outcome, while thrombosis of the transverse sinus was associated with a more favorable outcome, regardless of the side of the thrombosed sinus (Tables 4 and 7, Fig. 3). A simple explanation for this finding might be the moderate consequences of a unilateral thrombosed transverse sinus, compared to thrombosis of a “midline” venous structure without collateral or contralateral outflow.13

Two-thirds of the women who underwent neurosurgical procedures in our case series were discharged with an unfavorable outcome (Table 2). This might partly be explained by the greater severity of clinical course of CVT in these cases and predictors that are independent of the surgical intervention (Fig. 3). This poses the question whether an intervention alters the devastating natural course of severe CVT with elevated ICP. For patients with refractory ICP elevation after decompressive surgery, the addition of medical ICP treatment including barbiturate coma and induced hypothermia might be last-resort options with the potential for high morbidity in combination with mandatory anticoagulation regimes.

Our study has limitations. Because of the small size of this retrospective study, our findings should be interpreted with caution. Only univariate analysis was indicated, and the positive findings are not necessarily robust. Furthermore, we relied on the GSC score that was documented on admission and not during hospitalization. Therefore, a statement regarding clinical decline and its time course is not possible based on the current data. Nevertheless, our findings are in accordance with those of previous studies and were made in a homogeneous population of women with CHC intake without other morbidities likely to cause...
CVT. We have tentatively identified clinical and radiological predictive factors for a severe clinical course. Prospective studies in large cohorts are needed to validate the predictive value of these factors for the invasive and surgical treatment of elevated ICP.

TABLE 5. Clinical presentation at admission stratified by severity of clinical course

| Characteristic                        | Mild (84.2) | Severe (15.8) | p Value |
|---------------------------------------|-------------|---------------|---------|
| No. of pts (%)                        | 48          | 9             |         |
| Missing data for GCS score            | 1 (2.1)     | 1 (11.1)      |         |
| Missing data for focal neurology      | 1 (2.1)     | 2 (22.2)      |         |
| Missing data for seizures             | 1 (2.1)     | 4 (44.4)      |         |
| GCS score                             |             |               |         |
| Median                                | 15          | 9             | 0.004†  |
| SD                                    | 1.0         | 3.5           |         |
| Increased ICP§                        | 14 (29.2)   | 7 (77.8)      | 0.009‡  |
| Seizures                              | 23 (48.9)   | 1 (20)        | 0.356‡  |

Data are number of patients (%) unless otherwise indicated. Statistical significance was set at p ≤ 0.05.

† Mann-Whitney U-test.
‡ Fisher’s exact chi-square test.
§ Defined as ≥15 mm Hg in lumbar puncture or clinical signs (e.g., headaches, nausea, vomiting, altered consciousness, papilledema).

TABLE 6. Clinical presentation at admission stratified by need for invasive ICP management

| Characteristic                        | No ICP Treatment | Invasive ICP Treatment | p Value |
|---------------------------------------|------------------|------------------------|---------|
| No. of pts (%)                        | 51 (89.5)        | 6 (10.5)               |         |
| GCS score                             |                  |                        |         |
| Median                                | 15               | 9                      | 0.004†  |
| SD                                    | 1.2              | 3.5                    |         |
| Increased ICP§                        | 14 (27.5)        | 6 (100)                | 0.001‡  |
| Seizures                              | 24 (47.0)        | 0 (16.7)               | 0.120‡  |
| Focal neuro deficit of cerebral origin| 25 (49.0)        | 5 (83.3)               | 0.056‡  |
| Quadriparesis                         | 1 (2.0)          | 1 (16.7)               | 0.178‡  |
| Hemisyndrome                          | 10 (19.6)        | 3 (50)                 | 0.084‡  |
| Isolated focal deficit (incl aphasia) | 17 (33.3)        | 1 (16.7)               | —       |
| CN deficit                            | 11 (21.6)        | 3 (50.0)               | 0.103‡  |
| Eye movement (III/IV/VI)              | 5 (9.8)          | 3 (50.0)               | 0.019‡  |
| Upper CNs (V, VII, VIII)              | 8 (15.7)         | 0 (0.0)                | —       |
| Lower CNs (IX, X, XI)                 | 2 (4.0)          | 0 (0.0)                | —       |

CN = cranial nerve; incl = including; neuro = neurological.
Data are number of patients (%) unless otherwise indicated. Some patients presented with more than 1 deficit. Statistical significance was set at p ≤ 0.05.
† Mann-Whitney U-test.
‡ Fisher’s exact chi-square test.
§ Defined as ≥15 mm Hg in lumbar puncture or clinical signs (e.g., headaches, nausea, vomiting, altered consciousness, papilledema).

Conclusions

The rare case of CVT associated with CHC use that may require neurosurgical procedures and other medical therapies to control elevated ICP remains a serious complication. Clinical and radiological factors on admission may partly predict such invasive interventions. The addition of known medical strategies for refractory ICP might lead to a higher rate of infectious, thromboembolic, and hemorrhagic complications and higher morbidity. The significance of these factors needs to be further investigated in prospective multicenter studies.

Acknowledgments

We thank Andrea Roethlisberger for orthography and language revision and Selina Ackermann for manuscript preparation and submission support.

References

1. Amoozegar F, Ronksley PE, Sauve R, Menon BK: Hormonal contraceptives and cerebral venous thrombosis risk: a systematic review and meta-analysis. Front Neurol 6:7, 2015
2. Andresen M, Gazmuri JT, Marín A, Regueira T, Rovegno M: Hemorrhagic complications and higher morbidity. The significance of these factors needs to be further investigated in prospective multicenter studies.
3. Bezemer ID, van der Meer FJ, Eijkenboom JC, Rosendaal FR, Doggen CJ: The value of family history as a risk indicator for cerebral venous thrombosis. Arch Intern Med 169:610–615, 2009
4. Bhogal P, AlMatter M, Aguilar M, Nakagawa I, Ganslandt O, Bäzner H, et al: Cerebral venous sinus thrombosis: endovascular treatment with rheolyis and aspiration thrombectomy. Clin Neuroradiol 27:335–340, 2017
